The ARPIN Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of HT29 cells carrying a disruption in the ARPIN gene, which encodes an inhibitor of actin nucleation. This loss-of-function model enables the study of ARPIN-dependent regulation of the actin cytoskeleton and cell migration in a human colorectal adenocarcinoma background.
HT29 cells are a widely used epithelial cell line derived from a 44-year-old Caucasian female with colorectal adenocarcinoma. These cells exhibit an undifferentiated phenotype under standard culture conditions but can undergo enterocytic differentiation in response to various stimuli, making them a versatile model for intestinal epithelial biology and colorectal cancer research.
ARPIN functions as a negative regulator of the Arp2/3 complex by physically interacting with ARPC2 and ARPC3 subunits, thereby blocking nucleation of branched actin filaments. This inhibition is crucial for restricting lamellipodia protrusion and cell migration. ARPIN activity is under the control of upstream signaling by Rac1 and Cdc42 GTPases, which act through the WAVE and N-WASP pathways to promote Arp2/3 activation at the leading edge. Consequently, genetic disruption of ARPIN removes this negative feedback, leading to enhanced Arp2/3-mediated actin polymerization, increased lamellipodial dynamics, and altered migratory behavior.
In the context of HT29 colorectal adenocarcinoma cells, loss of ARPIN function provides a powerful platform to dissect the molecular mechanisms governing cancer cell motility and invasion. Given the critical role of actin cytoskeletal remodeling in tumor metastasis, this knockout model is well suited for investigating how aberrant activation of the Arp2/3 complex contributes to the invasive phenotype of colorectal cancer cells. The interplay between ARPIN and upstream oncogenic pathways, including PI3K signaling, further positions this model for studies on targeted therapeutic strategies aimed at inhibiting metastatic progression.
Typical applications include cell migration assays such as scratch wound healing and Boyden chamber invasion assays, as well as high-resolution imaging of F-actin dynamics using phalloidin staining or live-cell microscopy. Researchers can also combine this knockout model with pharmacological inhibitors of Arp2/3 or PI3K to validate pathway dependencies. Immunofluorescence and Western blot analyses of lamellipodial markers and Arp2/3 complex components provide complementary readouts. For more information or technical support, please contact Ascent Research.
